Cytek Biosciences Inc (CTKB) financials
Cytek Biosciences revenue and earnings by year
Cytek Biosciences's revenue was $201 million in the fiscal year to December 31, 2025, up 0.5% from the year before. Net income was -$66.5 million, -33.0% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 23.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 201 | 200 | 193 | 164 | 128 | 93 | 58 |
| Revenue growth | 0.5% | 3.9% | 17.7% | 28.2% | 37.8% | 60.4% | — |
| Gross profit | 104 | 111 | 109 | 101 | 79 | 52 | 29 |
| Gross margin | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% | 49.5% |
| Operating income | -40 | -21 | -28 | -2 | 9 | 14 | -17 |
| Operating margin | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% | 14.7% | -29.8% |
| Net income | -67 | -6 | -12 | 3 | 3 | 19 | -17 |
| Net margin | -33.0% | -3.0% | -6.3% | 1.6% | 2.3% | 20.9% | -29.1% |
| Diluted EPS | -$0.51 | -$0.05 | -$0.09 | $0.02 | $0.00 | $0.09 | — |
| Free cash flow | -9 | 22 | 0 | -22 | 0 | 14 | -15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CTKB in Markets.
How Cytek Biosciences makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $32.6M | 67.6% |
| Services | $15.6M | 32.4% |
See also: CTKB returns
No forecast, no recommendation. This page describes Cytek Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.